Evidence map›Paper›PMID 33685452›Full record

ReviewCancer cell international2021

Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature.

Surendar Aravindhan, Sura Salman Ejam, Methaq Hadi Lafta, Alexander Markov, Alexei Valerievich Yumashev, Majid Ahmadi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Innovative landscapes in intraperitoneal therapy of ovarian cancer.Drug delivery and translational research · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Surendar AravindhanDepartment of Pharmacology, Saveetha dental College and hospital, Saveetha institute of medical and technical sciences, Chennai, India. surendararavindhan@ieee.org.
Sura Salman EjamDepartment of Pathology, College of Medicine, University of Babylon, Babylon, Iraq.
Methaq Hadi LaftaIraqi Ministry of Education, Baghdad, Iraq.
Alexander MarkovTyumen State Medical University, Tyumen, Russian Federation.
Alexei Valerievich YumashevDepartment of Prosthetic Dentistry, Sechenov First Moscow State Medical University Moscow, Moscow, Russian Federation.
Majid AhmadiStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Ahmadi.m@tbzmed.ac.ir.ORCID http://orcid.org/0000-0003-4787-5261
Iraqi University · IQSaveetha University · INSechenov University · RUTabriz University of Medical Sciences · IRTyumen State Medical University · RUUniversity of Babylon · IQ

Funding

Tabriz University of Medical Sciences 65951
6 · The paper itself

Abstract

A crosstalk established between tumor microenvironment and tumor cells leads to contribution or inhibition of tumor progression. Mesenchymal stem cells (MSCs) are critical cells that fundamentally participate in modulation of the tumor microenvironment, and have been reported to be able to regulate and determine the final destination of tumor cell. Conflicting functions have been attributed to the activity of MSCs in the tumor microenvironment; they can confer a tumorigenic or anti-tumor potential to the tumor cells. Nonetheless, MSCs have been associated with a potential to modulate the tumor microenvironment in favouring the suppression of cancer cells, and promising results have been reported from the preclinical as well as clinical studies. Among the favourable behaviours of MSCs, are releasing mediators (like exosomes) and their natural migrative potential to tumor sites, allowing efficient drug delivering and, thereby, efficient targeting of migrating tumor cells. Additionally, angiogenesis of tumor tissue has been characterized as a key feature of tumors for growth and metastasis. Upon introduction of first anti-angiogenic therapy by a monoclonal antibody, attentions have been drawn toward manipulation of angiogenesis as an attractive strategy for cancer therapy. After that, a wide effort has been put on improving the approaches for cancer therapy through interfering with tumor angiogenesis. In this article, we attempted to have an overview on recent findings with respect to promising potential of MSCs in cancer therapy and had emphasis on the implementing MSCs to improve them against the suppression of angiogenesis in tumor tissue, hence, impeding the tumor progression.

Indexed as

Anti-angiogenesisMesenchymal stem cellsTumor microenvironmentTumor therapy

Identifiers

PMID33685452
PMCPMC7938588
OpenAlexW3135638864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.